FDA Webview
X
about-us-banner

FDA Related News

Home / Articles / FDA Related News
Federal Register

Panel to Discuss Mallinckrodts NDA for Terlipressin

Federal Register notice: FDA announces a 7/15 Cardiovascular and Renal Drugs Advisory Committee online meeting to review a Mallinckrodt NDA for terlip...

Federal Register

Stakeholder Participation for Drug User Fee Reauthorization

Federal Register notice: FDA seeks patient and consumer advocacy groups, healthcare professionals, and scientific and academic experts to participate ...

Human Drugs

FDA Accepts for Review Leos Talokinumab BLA

FDA accepts for review Leo Pharmas BLA for tralokinumab to treat adults with atopic dermatitis.

Human Drugs

Brilinta sNDA Accepted for Reducing Strokes

FDA accepts for priority review an AstraZeneca supplemental NDA for Brilinta (ticagrelor) for reducing subsequent strokes in patients who experienced ...

Medical Devices

Baxter Bone Graft Cleared

FDA clears a Baxter International 510(k) for the AltaporeShape Bioactive Bone Graft, which is intended to enhance bone growth and help achieve fusion.

Federal Register

Info Collection on Opioid Abuse Deterrent Formulations

Federal Register notice: FDA sends to OMB a new information collection entitled Health Care Providers Understanding of Opioid Analgesic Abuse Deterren...

Human Drugs

Court Says it Can Hear Paragraph IV Conversion Case

Two Gibbons attorneys say the Delaware federal court has ruled that it has subject matter jurisdiction in a generic drug patent case even if the defen...

Federal Register

Study of Disclosures to Physicians on Unapproved Uses

Federal Register notice: FDA seeks comments on a proposed information collection entitled Study of Disclosures to Health Care Providers Regarding Data...

Human Drugs

CGMP, Other Issues at Washington Homeopathic

FDA warns Washington Homeopathic Products about CGMP violations in its manufacturing of unapproved new drugs.

Human Drugs

Biogen Completes Alzheimers Treatment BLA

Biogen says it has filed a BLA with FDA for aducanumab to reduce the clinical decline of Alzheimers disease.